GC376 | 3CLpro inhibitor

Available Options

Size:PriceQuantity 
5 mg$45.00
25 mg$100.00
Request Quote / Bulk / Custom Size
Product Inquiry

GC376 (1416992-39-6) is a potent, reversible, covalent inhibitor of 3C- and 3C-like (3CLpro) proteases.1 It is a bisulfite adduct of GC373 (an aldehyde) thus it is a prodrug and is converted to the active aldehyde form under aqueous conditions.2 It is a broad-spectrum agent effective against many human and animal viruses including coronavirus and norovirus3 and others. GC376 is a promising candidate for further development as a SARS-CoV-2 therapeutic agent.4

References/Citations:

  1. Kim et al. (2012), Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses; J. Virol. 86 11754
  2. Lu et al. (2022), Crystallization of Feline Coronavirus Mpro With GC376 Reveals Mechanism of Inhibition; Front. Chem. 10 852210
  3. Takahashi et al. (2013), Structural and inhibitor studies of norovirus 3C-like proteases; Virus Res. 178 437
  4. Caceres et al. (2021), Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model; Sci. Rep. 11 9609
1416992-39-6, 3CLpro inhibitor, GC-376, GC376, GC376 supplier

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

GC376 (1416992-39-6) is a potent, reversible, covalent inhibitor of 3C- and 3C-like (3CLpro) proteases.1 It is a bisulfite adduct of GC373 (an aldehyde) thus it is a prodrug and is converted to the active aldehyde form under aqueous conditions.2 It is a broad-spectrum agent effective against many human and animal viruses including coronavirus and norovirus3 and others. GC376 is a promising candidate for further development as a SARS-CoV-2 therapeutic agent.4

References/Citations:

  1. Kim et al. (2012), Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses; J. Virol. 86 11754
  2. Lu et al. (2022), Crystallization of Feline Coronavirus Mpro With GC376 Reveals Mechanism of Inhibition; Front. Chem. 10 852210
  3. Takahashi et al. (2013), Structural and inhibitor studies of norovirus 3C-like proteases; Virus Res. 178 437
  4. Caceres et al. (2021), Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model; Sci. Rep. 11 9609